A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Dacarbazine
Indications Leiomyosarcoma; Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma
Focus Registrational; Therapeutic Use
Sponsors Eisai Co Ltd; Eisai Inc

01 Apr 2021 Results of an exploratory molecular analysis published in the Clinical Cancer Research
24 Jun 2020 Results assessing the molecular profile of LMS tumors from North American study sites assessing to identify potential predictive molecular factors for treatment with eribulin, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
08 May 2019 Results of a sub-group analysis assessing eribulin versus dacarbazine in patients with leiomyosarcoma (n=309) published in the British Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com